Clinical Trial

Disease: Soft Tissue Sarcoma, (NCT06117878)

Disease info:

Osteosarcoma is the most common primary bone cancer in children and teens, typically appearing during rapid growth in adolescence. It can also occur in adults over the age of 60. The tumour usually develops in the long bones of the legs, especially near the knee, or the upper arm near the shoulder, but it can start in any bone. 

The exact cause remains unclear. Some cases run in families and are linked to genetic changes, including mutations associated with familial retinoblastoma, a childhood eye cancer. Rapid bone growth during adolescence, male sex, and certain inherited genetic conditions can increase risk.

Early signs often include persistent bone pain near a joint that may be mistaken for growing pains. Other symptoms can include tenderness, swelling, or redness at the tumour site, limping if a leg is affected, pain when lifting if an arm is involved, limited joint movement, and bone fractures after minor injuries or normal activity.

Source: Osteosarcoma: MedlinePlus Medical Encyclopedia

Frequency:
Each year, about 1,000 new cases of osteosarcoma are diagnosed in the United States. -https://www.cancer.org
Official title:
An Open, Single Center Exploratory Study to Evaluate Safety and Efficacy of NK510 for Patients With Osteosarcoma and Soft Tissue Sarcoma
Who:

Contact 

Name: Jun Yan, PhD

Phone: +8618621668515

Email: yanjun@basetherapeutics.com

 

Contact Backup

Name: Yingqi Hua, PhD

Phone: +86 138 1765 1474

Email: hua_yingqi@163.com

Sponsor:

Base Therapeutics (Shanghai) Co., Ltd.
 

Partners:

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
 

Locations:

Shanghai, China

Shanghai General Hospital, Shanghai, China

Study start:
Sep. 1, 2022
Enrollment:
12
Gene editing method:
AccuBase® base editor
Type of edit:
Gene knockout and gene knock in
Gene:
Knockout of PD-1 and knock in of CD16
Delivery method:
- Ex-vivo
Indicator
IND Enabling Pre-clinical
Phase I Safety
Phase II Safety and Dosing
Phase III Safety and Efficacy

Status: Active recruiting

Description

This study will evaluate the safety and efficacy of NK510 in the treatment of Osteosarcoma and Soft Tissue Sarcoma.NK510 will be administered by intravenous injection. The safety and efficacy of this treatment will be evaluated.

Last updated: Sep. 22, 2025
close
Search CRISPR Medicine